The FDA’s crackdown on pharma advertising has accelerated, and failing to comply could be costly for drugmakers. This report examines what the spate of recent enforcement letters means for pharma creative, claims, and advertising channels, and how marketers can prepare for greater scrutiny.

Key Question: How can pharma brands and agencies adjust advertising strategies to mitigate regulatory risks highlighted by recent FDA enforcement letters?

Key Stat: The FDA sent 28 enforcement letters to pharma companies so far this year—that’s more than four times the number issued in any recent full year.